Intec Pharma Ltd (NASDAQ:NTEC) has earned a consensus recommendation of “Hold” from the eight research firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $0.88.
Several research firms have recently commented on NTEC. Roth Capital lowered shares of Intec Pharma from a “buy” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $1.00 in a research report on Friday, October 11th. LADENBURG THALM/SH SH reissued a “hold” rating on shares of Intec Pharma in a report on Monday, August 12th. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Wednesday, October 16th. ValuEngine lowered shares of Intec Pharma from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, HC Wainwright reaffirmed a “hold” rating on shares of Intec Pharma in a report on Monday.
Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Intec Pharma during the third quarter worth approximately $96,000. JPMorgan Chase & Co. purchased a new stake in shares of Intec Pharma in the second quarter valued at approximately $125,000. Taylor Frigon Capital Management LLC purchased a new stake in shares of Intec Pharma in the third quarter valued at approximately $302,000. Morgan Stanley raised its stake in shares of Intec Pharma by 38.4% during the 2nd quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock worth $356,000 after buying an additional 22,715 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Intec Pharma during the 2nd quarter valued at approximately $593,000. 17.21% of the stock is owned by institutional investors and hedge funds.
Intec Pharma (NASDAQ:NTEC) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.10). On average, research analysts anticipate that Intec Pharma will post -0.92 earnings per share for the current fiscal year.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Read More: What is the definition of a trade war?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.